In its 12 November 2026 investor webinar and business update, EVE Health Group (ASX: EVE) outlined a three-channel strategy built on its patent-pending nano-emulsion platform. The presentation positioned Libbo, a vardenafil oral dissolving film, as the proof of concept, noting that the platform is the asset.
Libbo is supplied under SAS-B today. An exclusive Australian compounding agreement with Optimal Pharmacy Plus Stafford was signed on 10 November 2026, with first supply pending.
EVE Health Group outlines three-channel strategy built on its patent-pending nano-emulsion platform
The presentation described three commercial pathways running off one platform:
- SAS-B: active today.
- Optimal compounding: signed, with first supply pending.
- Full product registration: follows the bioequivalence study.
Management described the model as capital-light and partner-led, with no manufacturing or compounding infrastructure for EVE to fund.
Why Libbo targets patients current tablets are losing
The presentation opened with the market. An estimated 322m men globally are affected by erectile dysfunction (ED, projected 2025), and the global treatment market is sized at USD 5.7B (2026). Around 50% of patients discontinue PDE5 inhibitors within one year.
In Australia, about 61% of men aged 45 and over report some degree of ED. That figure comes from an older cohort study (Weber et al., 2013), not a current national survey.
Management contrasted onset times. Conventional tablets are typically 45 to 60 minutes (vardenafil) or 1 hour or more (sildenafil and tadalafil), while Libbo is described as approximately 15 minutes. That figure is based on formulation design and an early 10-person observational study, with clinical validation pending.
The presentation also cited current treatment shortfalls:
- 30-35% of patients report an inadequate or variable response.
- Food effect of up to 35% has been reported for selected tablet formats.
Libbo absorbs transmucosally, meaning through the lining of the mouth. This route bypasses the gut and first-pass liver metabolism, the process in which the liver breaks down part of a swallowed drug before it reaches the bloodstream. Those steps are what slow onset and make response less consistent with conventional tablets.
Validation steps include a pilot pharmacokinetic (PK) study, with dosing targeted for Q4 2026, and a planned bioequivalence study.
The Optimal compounding agreement
The agreement is a binding Master Compounding and Profit Share Agreement, signed on 10 November 2026. Key terms are below.
| Term | Detail |
| Profit share | 75% EVE / 25% Optimal, of profit available for distribution after direct costs of compounding and delivery |
| Upfront fees | None payable by EVE |
| Exclusivity | Optimal is the exclusive Australian compounder of the initial men’s sexual health range |
| Intellectual property | EVE retains all IP, product and formulation rights |
Separate from Libbo
The agreement does not include Libbo and is independent of the Libbo registration program.
The initial range covers three products: ED, premature ejaculation (PE) and an ED/PE combination, in oral film or oral spray formats. Comparative performance remains subject to validation.
First supply is subject to conditions, including technology transfer and validation. The agreement carries no minimum volumes or guaranteed revenue, and EVE cannot yet estimate revenue.
The Libbo launch built an integrated model of telehealth prescribing and home delivery, an infrastructure that the compounded range is expected to reuse through Australian telehealth partners.
A platform and pipeline beyond men’s health
Management described the platform process in four steps:
- A proven compound with poor aqueous solubility limits conventional tablet performance.
- A proprietary process converts the molecule into a stable nano-emulsion with improved effective solubility.
- The result is delivered as an oral film or oral spray.
- The aim is faster onset and improved bioavailability.
The pipeline includes:
- PE, ED/PE combination and benign prostatic hyperplasia (BPH) programs, all in development.
- An apixaban reformulation, in pre-BE development.
- Rosuvastatin and atorvastatin reformulations, in development.
The presentation pointed to a patent cliff, where high-value medicines lose exclusivity. Apixaban (Eliquis) has global sales of USD 12.2B and is the only target flagged as pre-BE. Rivaroxaban, Xtandi, Farxiga and Imbruvica are at the screening stage only. Market values are directional, based on 2023 and 2024 sales sources, and expiry dates are indicative.
Management said the accelerated pathway focuses on bioequivalence for established molecules rather than Phase I to III development.
Corporate snapshot
Figures presented as at 10 November 2026 unless stated:
- Share price: A$0.014
- Market capitalisation: A$4.9m
- Cash (30 September 2026): A$0.84m
- Enterprise value: A$4.1m
- Debt: nil
- Shares on issue: 352m
- Options on issue: 165m (4-6 cent exercise price)
Ownership is led by A-Won Pharma Pty Ltd at 45%, Dr Stuart Gunzburg at 23% and AQA Corporation Pty Ltd at 15%.
EVE’s quarterly cash position shows the funding runway is short relative to the clinical timetable, with the company estimating roughly 2.1 quarters of cover and a research tax incentive refund expected in the December quarter.
What happens next for EVE
- First compounded supply: near-term, after technology transfer and validation with Optimal, via Australian telehealth partners.
- Libbo pilot PK study: dosing targeted Q4 2026, with data in early 2027.
- Libbo pivotal bioequivalence study: targeted to commence Q1 2027, subject to satisfactory pilot outcomes.
- PE program pre-BE progress update: H1 2027.
- Apixaban pre-BE work completion: H2 2027.
- Potential Libbo product registration submission: H2 2027, following BE study completion and subject to clinical and regulatory outcomes.
Timing reflects the current corporate planning view and is subject to clinical, regulatory and operational dependencies. Preliminary partner discussions are underway across Asia, the Middle East, Europe and North America.
When big ASX news breaks, our subscribers know first
Ready To Learn More About EVE Health Group’s Nano-Emulsion Platform?
EVE Health Group is advancing a patent-pending nano-emulsion platform through three commercial pathways, led by the Libbo oral dissolving film and a newly signed exclusive compounding agreement. With a pilot PK study targeted for Q4 2026 and a pipeline spanning men’s health and apixaban reformulation, the platform sits at the centre of the investment case.
Explore the company’s projects, milestones and partnership progress by visiting the EVE Health Group website. Investors can review the latest updates to see how the platform strategy is unfolding.